vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Mirion Technologies, Inc. (MIR). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $257.6M, roughly 1.9× Mirion Technologies, Inc.). On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 27.5%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 11.5%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Mirion Technologies, Inc. is a global provider of radiation detection, monitoring, and safety solutions. Its core offerings include personal dosimetry systems, radiation imaging equipment, and risk management software, serving nuclear power, healthcare, defense, and industrial sectors across North America, Europe, and the Asia Pacific.

CLOV vs MIR — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.9× larger
CLOV
$487.7M
$257.6M
MIR
Growing faster (revenue YoY)
CLOV
CLOV
+17.2% gap
CLOV
44.7%
27.5%
MIR
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
11.5%
MIR

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
MIR
MIR
Revenue
$487.7M
$257.6M
Net Profit
$-49.3M
Gross Margin
46.2%
Operating Margin
-10.1%
1.4%
Net Margin
-10.1%
Revenue YoY
44.7%
27.5%
Net Profit YoY
-123.2%
EPS (diluted)
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
MIR
MIR
Q1 26
$257.6M
Q4 25
$487.7M
$277.4M
Q3 25
$496.6M
$223.1M
Q2 25
$477.6M
$222.9M
Q1 25
$462.3M
$202.0M
Q4 24
$337.0M
$254.3M
Q3 24
$331.0M
$206.8M
Q2 24
$356.3M
$207.1M
Net Profit
CLOV
CLOV
MIR
MIR
Q1 26
Q4 25
$-49.3M
$17.3M
Q3 25
$-24.4M
$2.9M
Q2 25
$-10.6M
$8.3M
Q1 25
$-1.3M
$300.0K
Q4 24
$-22.1M
$15.0M
Q3 24
$-9.2M
$-13.6M
Q2 24
$7.4M
$-11.7M
Gross Margin
CLOV
CLOV
MIR
MIR
Q1 26
46.2%
Q4 25
48.8%
Q3 25
46.8%
Q2 25
46.0%
Q1 25
47.6%
Q4 24
48.1%
Q3 24
24.5%
44.9%
Q2 24
30.3%
47.0%
Operating Margin
CLOV
CLOV
MIR
MIR
Q1 26
1.4%
Q4 25
-10.1%
9.2%
Q3 25
-4.9%
3.3%
Q2 25
-2.2%
4.4%
Q1 25
-0.3%
4.3%
Q4 24
-6.4%
11.4%
Q3 24
-2.7%
-0.8%
Q2 24
2.0%
1.1%
Net Margin
CLOV
CLOV
MIR
MIR
Q1 26
Q4 25
-10.1%
6.2%
Q3 25
-4.9%
1.3%
Q2 25
-2.2%
3.7%
Q1 25
-0.3%
0.1%
Q4 24
-6.6%
5.9%
Q3 24
-2.8%
-6.6%
Q2 24
2.1%
-5.6%
EPS (diluted)
CLOV
CLOV
MIR
MIR
Q1 26
$-0.01
Q4 25
$0.07
Q3 25
$0.01
Q2 25
$0.03
Q1 25
$0.00
Q4 24
$0.08
Q3 24
$-0.07
Q2 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
MIR
MIR
Cash + ST InvestmentsLiquidity on hand
$78.3M
$397.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$1.9B
Total Assets
$541.0M
$3.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
MIR
MIR
Q1 26
$397.9M
Q4 25
$78.3M
$412.3M
Q3 25
$933.2M
Q2 25
$262.6M
Q1 25
$185.8M
Q4 24
$194.5M
$175.2M
Q3 24
$288.0M
$133.3M
Q2 24
$254.8M
$122.2M
Total Debt
CLOV
CLOV
MIR
MIR
Q1 26
Q4 25
Q3 25
$444.8M
Q2 25
$444.9M
Q1 25
$686.6M
Q4 24
$686.4M
Q3 24
$685.1M
Q2 24
$684.1M
Stockholders' Equity
CLOV
CLOV
MIR
MIR
Q1 26
$1.9B
Q4 25
$308.7M
$1.9B
Q3 25
$340.9M
$1.8B
Q2 25
$344.2M
$1.5B
Q1 25
$336.1M
$1.5B
Q4 24
$341.1M
$1.5B
Q3 24
$342.2M
$1.5B
Q2 24
$324.9M
$1.5B
Total Assets
CLOV
CLOV
MIR
MIR
Q1 26
$3.5B
Q4 25
$541.0M
$3.6B
Q3 25
$559.7M
$3.5B
Q2 25
$575.0M
$2.7B
Q1 25
$583.7M
$2.6B
Q4 24
$580.7M
$2.6B
Q3 24
$653.0M
$2.7B
Q2 24
$674.2M
$2.6B
Debt / Equity
CLOV
CLOV
MIR
MIR
Q1 26
Q4 25
Q3 25
0.24×
Q2 25
0.30×
Q1 25
0.46×
Q4 24
0.46×
Q3 24
0.45×
Q2 24
0.45×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
MIR
MIR
Operating Cash FlowLast quarter
$-66.9M
$18.9M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
MIR
MIR
Q1 26
$18.9M
Q4 25
$-66.9M
$73.0M
Q3 25
$12.1M
$22.3M
Q2 25
$5.4M
$12.4M
Q1 25
$-16.3M
$35.6M
Q4 24
$34.8M
$60.8M
Q3 24
$50.0M
$17.1M
Q2 24
$44.8M
$15.2M
Free Cash Flow
CLOV
CLOV
MIR
MIR
Q1 26
Q4 25
$-69.0M
$63.2M
Q3 25
$11.4M
$13.0M
Q2 25
$4.8M
$3.6M
Q1 25
$-16.5M
$27.1M
Q4 24
$33.3M
$49.1M
Q3 24
$49.6M
$3.9M
Q2 24
$44.4M
$4.1M
FCF Margin
CLOV
CLOV
MIR
MIR
Q1 26
Q4 25
-14.1%
22.8%
Q3 25
2.3%
5.8%
Q2 25
1.0%
1.6%
Q1 25
-3.6%
13.4%
Q4 24
9.9%
19.3%
Q3 24
15.0%
1.9%
Q2 24
12.5%
2.0%
Capex Intensity
CLOV
CLOV
MIR
MIR
Q1 26
Q4 25
0.4%
3.5%
Q3 25
0.1%
4.2%
Q2 25
0.1%
3.9%
Q1 25
0.0%
4.2%
Q4 24
0.5%
4.6%
Q3 24
0.1%
6.4%
Q2 24
0.1%
5.4%
Cash Conversion
CLOV
CLOV
MIR
MIR
Q1 26
Q4 25
4.22×
Q3 25
7.69×
Q2 25
1.49×
Q1 25
118.67×
Q4 24
4.05×
Q3 24
Q2 24
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

MIR
MIR

Product$197.0M76%
Service$60.6M24%

Related Comparisons